Extended Interval Dosing of Gentamicin in Neonates

Current gentamicin dosing at the Children's Hospital is based on the previous projects completed at LHSC. Different gentamicin dosing recommendations exist depending on the reference used. This study would help validate if the current extended interval dosing in neonates is still achieving target gentamicin concentration levels. We will compare the results of the current study to our historic data. The results will help determine if infants are receiving effective and safe treatment with gentamicin. Depending on the results of the study, further evaluation on changes to gentamicin dosing may be needed or an official guideline may be published if gentamicin levels are being adequately achieved with the current dosing. This official guideline will help prescribers at the Children's Hospital and hospitals in the surrounding region that will adopt our dosing when treating infants. There will be an overall benefit to prescribers and patients ensuring safe and effective of gentamicin dosing is followed. If the infant meets the study inclusion criteria, a letter of information will be provided to the parent(s)/guardian(s) if agreeable using REDCap. Consent must be obtained prior to enrollment.

Inclusion criteria

• Neonates up to 7 days of age,
• Neonate must be on gentamicin, and
• Gentamicin trough and peak levels must be available for the third dose of gentamicin.

Exclusion criteria

• Incorrect dose for weight (+/- 10% allowed to account for dose rounding)
• Multiple levels from the same patient; only the first set of levels will be collected
• Baseline renal dysfunction (e.g. congenital kidney disease)
• On other nephrotoxic or ototoxic drugs concurrently with the first 3 days of gentamicin